Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases

A compound of formula (I)

• including the deuterated isomers, stereoisomers and the tautomeric forms thereof,
• wherein
• Y1 represents a bond or CR7R8;
• wherein
• Y2 represents a bond or CR7R8, wherein R7 and R8 are independently selected from hydrogen and C1-C4 alkyl, and A represents CH or N;
• or
• Y2 is CR9 and A is C thus forming a C═C bond, wherein R9 is hydrogen or C1-C4 alkyl;
• wherein Y3 represents CH;
• or Y1 and Y2 represent a bond, and a further —CH2— is present directly connecting A and Y3 to form a bridged 5-membered cyclic hydrocarbon;
• wherein Y4 represents OH, OR14 or R14 wherein R14 is C1-C4 alkyl;
• wherein Q represents a bond or a 5- to 6-membered aromatic ring,
• wherein said 5- to 6-membered aromatic ring optionally comprises 1-3 heteroatoms,
• wherein said 5- to 6-membered aromatic ring is optionally substituted with one or more substituents each independently selected from the group consisting of C1-C4 alkyl,
• halogen,
• OR13 wherein R13 is H or C1-C4 alkyl,
• NR10R11 where R10 and R11 are independently selected from H and C1-C4 alkyl, or R10 and R11 form a C4, C5 or C6 membered ring,
• C1-C4 alkyl substituted with one or more halogen,
• C1-C4 alkyl substituted with OR12 wherein each R12 is H or C1-C4 alkyl;
• wherein if Q represents a bond, Y4 is selected from the group consisting of
• phenyl,
• pyrazolyl,
• isoxazolyl,
• thiadiazolyl,
• phenyl substituted with C1-C4 alkyl,
• pyrazolyl substituted with C1-C4 alkyl,
• isoxazolyl substituted with C1-C4 alkyl, and
• thiadiazolyl substituted with C1-C4 alkyl;
• wherein L1 is selected from the group consisting of
• a bond,
• C1-C4 alkyl, and
• C1-C4 alkyl substituted with one or more substituents each independently selected from the group consisting of
• C1-C4 alkyl,
• halogen,
• oxo,
• OR7 wherein R7 independently is hydrogen or C1-C4 alkyl, and
• C1-C4 alkyl substituted with one or more halogen;
• wherein L2 is selected from the group consisting of
• a bond,
• C1-C4 alkyl, and
• a 3-7 membered saturated ring optionally containing one or more heteroatom(s), the heteroatom being a nitrogen
• wherein each of said C1-C4 alkyl and said 3-7 membered saturated ring are optionally substituted with one or more substituents each independently selected from the group consisting of
• C1-C4 alkyl,
• halogen,
• OR15 wherein R15 independently is hydrogen or C1-C4 alkyl, and
• C1-C4 alkyl substituted with one or more halogen;
• wherein p is an integer selected from 0 and 1;
• wherein R1 is selected from the group consisting of thiazolyl, pyridyl, thiazolyl substituted with one or more halogen and pyridyl substituted with one or more halogen;
• wherein R3 is C1-C3alkyl;
• and
• wherein R4, R5 and R6 each independently are selected from the group consisting of hydrogen, C1-C3 alkyl and halogen;
• or a pharmaceutically acceptable salt or a solvate thereof.